Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study

dc.contributor.authorGarcía Carnero, Lourdes
dc.contributor.authorAbelenda Alonso, Gabriela
dc.contributor.authorSantos Puig, Marc
dc.contributor.authorPadullés Zamora, Ariadna
dc.contributor.authorRibera, Clara
dc.contributor.authorLamiel, Alberto
dc.contributor.authorCosta Primo, Rosa Maria
dc.contributor.authorGonzález de Aledo, Manuel
dc.contributor.authorGranada, Rosa
dc.contributor.authorGumucio, Víctor Daniel
dc.contributor.authorSantafosta, Eva
dc.contributor.authorGilabert, Marc
dc.contributor.authorBlanco Arévalo, Alejandro
dc.contributor.authorPuig Asensio, Mireia
dc.contributor.authorShaw, Evelyn
dc.contributor.authorCarratalà, Jordi
dc.contributor.authorGudiol González, Carlota
dc.date.accessioned2026-07-02T12:24:06Z
dc.date.available2026-07-02T12:24:06Z
dc.date.issued2026-04-20
dc.date.updated2026-05-26T12:30:49Z
dc.description.abstractBackground/Objectives: Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) represent a major therapeutic challenge, particularly in hospitalized and critically ill patients with limited treatment options. Cefiderocol, a novel siderophore cephalosporin, has demonstrated activity against a broad range of resistant Gram-negative pathogens. We aimed to evaluate the effectiveness and safety of cefiderocol for the treatment of MDR-GNB infection. Methods: We conducted a retrospective observational study including all adult patients who received >= 72 h of cefiderocol between November 2020 and October 2024 at a Spanish tertiary-care hospital. The primary outcome was clinical success, defined as survival and absence of clinical recurrence 30 days after cefiderocol initiation. Secondary outcomes included 30- and 90-day mortality, clinical and microbiological recurrence, emergence of resistance, and adverse events. Results: Eighty patients were included (median age 64 years [IQR 56-72]; 81.3% male). Respiratory (26.2%) and abdominal (22.5%) infections were the most common, and 20% presented with bacteremia. At infection onset, 26.2% had septic shock and 45% required intensive care unit admission. The three most frequently isolated pathogen was Pseudomonas aeruginosa (33.9%), followed by Enterobacterales (33%) and Stenotrophomonas maltophilia (30.1%). Clinical success was achieved in 67.5% of patients. Thirty and 90-day mortality rates were 27.5% and 36.5%, respectively. Recurrence within 90 days occurred in 5% of cases. Emergence of resistance was detected in one Klebsiella pneumoniae ST147 isolate, and serious adverse events occurred in 5% of patients. Conclusions: In a cohort including a substantial proportion of critically ill patients, cefiderocol was associated with favorable clinical outcomes and an acceptable safety profile. These findings suggest that cefiderocol may represent a useful therapeutic option for severe MDR-GNB infections in patients with limited treatment alternatives.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2079-6382
dc.identifier.pmid42041379
dc.identifier.urihttps://hdl.handle.net/2445/230390
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/antibiotics15040416
dc.relation.ispartofAntibiotics, 2026, vol. 15, num. 4, p. 416
dc.relation.urihttps://doi.org/10.3390/antibiotics15040416
dc.rightscc by (c) García Carnero, Lourdes et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCefalosporines
dc.subject.classificationMalalts en estat crític
dc.subject.classificationResistència als medicaments
dc.subject.otherCephalosporines
dc.subject.otherCritically ill
dc.subject.otherDrug resistance
dc.titleCefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
antibiotics-15-00416.pdf
Mida:
442.23 KB
Format:
Adobe Portable Document Format